Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
What is your preferred adjuvant systemic treatment for a patient with isolated melanoma brain metastasis following complete resection and SRS to the tumor bed?
Related Questions
Do you consider downstaging neoadjuvant cemiplimab for borderline resectable CSCC in order to facilitate surgical resection?
What criteria do you use to determine the resectability of mucosal melanoma of the H&N region?
What systemic therapy would you offer a patient with metastatic melanoma who is BRAF WT and developed metastases while on adjuvant nivolumab?
Any role for adjuvant systemic therapy for resected sebaceous skin carcinoma?
What scenario would flipped dosing versus standard dosing of Ipilimumab+Nivolumab be beneficial in metastatic melanoma?
Would you offer adjuvant immune checkpoint therapy for a patient with resected mucosal melanoma with a tumor thickness >4.0 mm with negative LN involvement?
How would you approach a 2 cm malignant primary cutaneous adnexal adenocarcinoma of the axilla s/p resection with positive margin who is unable to undergo additional surgery?
What scenario would prophylactic Tocilizumab be considered to prevent Ipilimumab+Nivolumab (immunotherapy) induced toxicity in malignant melanoma?
What role, if any, do biomarkers play in selecting appropriate patients for neoadjuvant cemiplimab in cutaneous squamous cell carcinoma?
How do you approach patients with polypoid/nodular melanoma for adjuvant therapy when Breslow depth is not available on pathology?